Evidence map›Paper›PMID 36909654›Full record

ArticleResearch square2023

Predictors of Cognitive Decline in Healthy Middle-Aged Individuals with Asymptomatic Alzheimer's Disease.

Raghav Tandon, Liping Zhao, Caroline M Watson, Morgan Elmor, Craig Heilman, Katherine Sanders, Chadwick M Hales, Huiying Yang, David W Loring, Felicia C Goldstein and 11 more

Open access · greenFull text readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Raghav TandonDepartment of Biomedical Engineering, Georgia Institute of Technology.
Liping ZhaoDepartment of Biostatistics and Bioinformatics, Emory School of Public Health.
Caroline M WatsonEmory Goizueta Alzheimer's Disease Research Center.
Morgan ElmorEmory Goizueta Alzheimer's Disease Research Center.
Craig HeilmanEmory Goizueta Alzheimer's Disease Research Center.
Katherine SandersEmory Goizueta Alzheimer's Disease Research Center.
Chadwick M HalesEmory Goizueta Alzheimer's Disease Research Center.
Huiying YangDepartment of Biostatistics and Bioinformatics, Emory School of Public Health.
David W LoringEmory Goizueta Alzheimer's Disease Research Center.
Felicia C GoldsteinEmory Goizueta Alzheimer's Disease Research Center.
John J HanfeltDepartment of Biostatistics and Bioinformatics, Emory School of Public Health.
Duc M DuongEmory Goizueta Alzheimer's Disease Research Center.
Erik C B JohnsonEmory Goizueta Alzheimer's Disease Research Center.
Alzheimer’s Disease Neuroimaging Initiative
Aliza P WingoDepartment of Psychiatry, Emory School of Medicine.
Thomas S WingoEmory Goizueta Alzheimer's Disease Research Center.
Blaine R RobertsCenter for Neurodegenerative Disease, Emory University.
Nicholas T SeyfriedEmory Goizueta Alzheimer's Disease Research Center.
Allan I LeveyEmory Goizueta Alzheimer's Disease Research Center.
Cassie S MitchellDepartment of Biomedical Engineering, Georgia Institute of Technology.
James J LahEmory Goizueta Alzheimer's Disease Research Center.
Emory University · USGeorgia Institute of Technology · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's DiseaseR01AG070937 · NIA · EMORY UNIVERSITY · PI LAH, JAMES J · 2021 to 2025
$35.2M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Amy D Rodriguez · 2020 to 2026
$29.0M
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
Inflamm-aging of osteoprogenitor cells: A therapeutic target for improved bone healing - Resubmission - 1 - Revision - 3R01AG056169 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LEUCHT, PHILIPP · 2018 to 2022
$2.4M
Inflamm-aging of osteoprogenitor cells: A therapeutic target for improved bone healingR56AG056169 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LEUCHT, PHILIPP · 2023 to 2023
$347k
NIA NIH HHS P30 AG066511NIA NIH HHS R01 AG056169NIA NIH HHS R01 AG070937NIA NIH HHS R56 AG056169NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG061357
6 · The paper itself

Abstract

Alzheimer's disease (AD) progresses through a lengthy asymptomatic period during which pathological changes accumulate prior to development of clinical symptoms. As disease-modifying treatments are developed, tools to stratify risk of clinical disease will be required to guide their use. In this study, we examine the relationship of AD biomarkers in healthy middle-aged individuals to health history, family history, and neuropsychological measures and identify cerebrospinal fluid (CSF) biomarkers to stratify risk of progression from asymptomatic to symptomatic AD. CSF from cognitively normal (CN) individuals (N=1149) in the Emory Healthy Brain Study were assayed for Aβ

Identifiers

PMID36909654
PMCPMC10002814
OpenAlexW4322630922

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read24
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.